Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade V good
|
New words:
absence, adequacy, anticoagulant, appealed, attest, attestation, bioequivalence, category, comment, concomitantly, DuPuy, effort, Euflexxa, fashion, Firm, improve, indentified, iv, lack, Lawrence, memorandum, modification, National, notifying, novelty, Nuflexxa, Oxadrin, oxandralone, payroll, percent, precedent, problem, Registered, resolution, respond, segregate, segregation, substance, taxable, toxicology, treasurer, treasury, workforce
Removed:
direct, SEC, shareholder, unmarketability
Filing tables
Filing exhibits
SVNT similar filings
Filing view
External links
Exhibit 32.2 |
STATEMENT PURSUANT TO 18 U.S.C. §1350
Pursuant to 18 U.S.C. §1350, the undersigned certifies that this Quarterly Report on Form 10-Q for the period ended September 30, 2004 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Savient Pharmaceuticals, Inc.
November 8, 2004 | By: |
/s/ Lawrence A. Gyenes |
Lawrence A. Gyenes Senior Vice President, Chief Financial Officer and Treasurer |
48